AI Summary
Hampel et al. review data on Alzheimer's disease biomarkers that are close to clinical use and discuss important factors for their development and implementation.
Hampel et al. review current data on blood-based biomarkers (BBBMs) for Alzheimer’s disease (AD) that are closest to clinical adoption, discussing important concepts and considerations for the development and implementation of AD BBBMs under a context-of-use framework.